Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021)
Atea Pharmaceuticals' (AVIR) quarterly Current Deferred Revenue came in at $192.2 million in Q3 2021, down 14.58% quarter-over-quarter from $225.0 million in Q2 2021.
Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021) Analysis & Trends
Atea Pharmaceuticals' Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $192.2 million for Q3 2021.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $192.2 million in Q3 2021; TTM through Sep 2021 was $192.2 million, a N/A change from a year earlier, with the FY2020 full-year figure at $301.4 million, changed N/A from the prior year.
- Current Deferred Revenue eased to $192.2 million in Q3 2021 per AVIR's latest filing, from $225.0 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $301.4 million in Q4 2020 and bottomed at $192.2 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Atea Pharmaceuticals | 376.19 Mn | 376.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 192.18 Mn |
| Jun 30, 2021 | 224.99 Mn |
| Mar 31, 2021 | 235.38 Mn |
| Dec 31, 2020 | 301.37 Mn |